[Effect of a new triphasic @entity172 - XXXX compound on the mouth mucosa, gingiva and gingival margin].

@entity172 @entity1 @entity548 @entity7828 @entity450 @entity1871 @entity2521 @entity7138
The new triphasic @entity172 - @entity1871 compound provides good contraception with a hormonal dosage that is sensibly lower than in the older compounds. Many of the risks connected with oral contraception are thus reduced. The study aims to show whether the triphasic compound has any side effects on the @entity7138 and on the gingival margin. Such effects have been noticed by several authors to be related to higher blood levels of @entity172 and @entity7828 , as in the treatment with monophasic compounds and in pregnancies. 30 @entity1 had an oral exam at the beginning of the study and were tested again after 3 cycles of treatment. The tests regarded the condition of the oral mucosa, the gingiva and the gingival margin. Besides, the coagulation factors were tested in relationship with the antithrombin III. In the majority of cases only moderate @entity450 was seen. 6 @entity1 showed @entity2521 with @entity548 while eating. All lesions were reversible. The blood tests did not show any significant change. These results need to be compared with those of a larger study and after several cycles of treatment.
